Abstract：
Severe asthma is a complex and heterogeneous chronic airway inflammatory disease. Current treatment strategies are increasingly focused on disease classification, facilitating the transition towards personalized medicine by integrating biomarkers and monoclonal antibodies for tailored therapeutic approaches. Several approved biological agents, including anti-immunoglobulin E (IgE), anti-interleukin (IL)-4, anti-IL-5, and anti-thymic stromal lymphopoietin (TSLP) monoclonal antibodies, have demonstrated significant efficacy in reducing asthma exacerbations, eosinophil counts, improving lung function, minimizing oral corticosteroid usage, and enhancing patients\' quality of life. The utilization of these biological agents has brought about profound transformations in the management of severe asthma. This article provides a comprehensive review on biomarkers and biological agents for severe asthma while emphasizing the increasing importance of further research into its pathogenesis and novel treatment modalities.
摘要：
重症哮喘是一种庞杂、异质性的慢性气道炎症性疾病。目前的治疗策略越来越集中在疾病分类上，通过整合生物标志物和单克隆抗体来定制治疗方法，促进向个性化医疗的过渡。几种批准的生物制剂，包括抗免疫球蛋白E（IgE），抗白细胞介素（IL）-4，抗IL-5和抗胸腺基质淋巴细胞生成素（TSLP）单克隆抗体，在减少哮喘恶化方面表现出显著的疗效，嗜酸性粒细胞计数,改善肺功能，尽量减少口服皮质类固醇的使用，提高患者的生活质量。这些生物制剂的利用在严重哮喘的管理中带来了深刻的转变。本文对重度哮喘的生物标志物和生物制剂进行了全面综述，同时强调了进一步研究其发病机制和新的治疗方式的重要性。
